{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:53:57Z","timestamp":1794322437735,"version":"4.9.0"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction\/Aims<\/jats:title>\n                    <jats:p>If myasthenia gravis (MG) symptoms are inadequately controlled, patients may experience exacerbations or life\u2010threatening myasthenic crises. Patients with inadequately controlled MG symptoms tend to be treated with chronic intravenous immunoglobulin (IVIg) therapy and\/or multiple immunosuppressant therapies (ISTs). This study aimed to examine disease burden, healthcare resource utilization, and associated costs in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective observational study using a claims database. Patients with MG were classified into three cohorts based on treatment over a 1\u2010y follow\u2010up period: (a) treated with four or more IVIg episodes (chronic IVIg cohort); (b) received two or more non\u2010steroidal ISTs (NSISTs) sequentially (multiple NSIST cohort); (c) received neither chronic IVIg nor multiple NSISTs (reference cohort). Incidences of crises and exacerbations and annual healthcare costs in each cohort were estimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 3516 patients with MG were included in the analysis. Compared with the reference cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092992), the MG crisis rate was approximately twice as high in both the chronic IVIg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009324) and multiple NSIST (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009291) cohorts (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001); and the MG exacerbation rate was approximately four\u2010fold higher in the chronic IVIg cohort (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and three\u2010fold higher in the multiple NSIST cohort (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Median annual MG\u2010related inflation\u2010adjusted total healthcare costs were higher in the chronic IVIg ($81,900) and multiple NSIST ($30,300) cohorts than in the reference cohort ($2540).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The burden of crises\/exacerbations was substantially higher and healthcare costs were considerably greater in patients with MG treated with chronic IVIg or multiple NSISTs than in patients not receiving these treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mus.27992","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T05:44:35Z","timestamp":1701236675000},"page":"157-165","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the\n                    <scp>United States<\/scp>"],"prefix":"10.1002","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-9479","authenticated-orcid":false,"given":"A.","family":"Parthan","sequence":"first","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-5104","authenticated-orcid":false,"given":"M.","family":"Royston","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6341-2155","authenticated-orcid":false,"given":"A.","family":"Thanataveerat","sequence":"additional","affiliation":[{"name":"Genesis Research Group  Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9989-2309","authenticated-orcid":false,"given":"E. L.","family":"East","sequence":"additional","affiliation":[{"name":"Genesis Research Group  Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6178-4043","authenticated-orcid":false,"given":"C. S.","family":"Parzynski","sequence":"additional","affiliation":[{"name":"Genesis Research Group  Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3432-9747","authenticated-orcid":false,"given":"A. A.","family":"Habib","sequence":"additional","affiliation":[{"name":"University of California  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.65.4.492"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.145987"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26114"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000257"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000301"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2019.15.3.376"},{"key":"e_1_2_12_13_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2016"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26447"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22212"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e31822c34dd"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.09.054"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/13548506.2020.1807577"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2015.01.022"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26694"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10891-1"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5256-6"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.27992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T23:53:08Z","timestamp":1705881188000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.27992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1002\/mus.27992"],"URL":"https:\/\/doi.org\/10.1002\/mus.27992","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"assertion":[{"value":"2022-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}